Rubicon Founders LLC Purchases Shares of 105,341 Agilon Health, Inc. $AGL

Rubicon Founders LLC purchased a new stake in Agilon Health, Inc. (NYSE:AGL) during the second quarter, HoldingsChannel.com reports. The firm purchased 105,341 shares of the company’s stock, valued at approximately $11,290,448,000. Agilon Health accounts for about 5.7% of Rubicon Founders LLC’s investment portfolio, making the stock its 3rd largest position.

Other institutional investors also recently made changes to their positions in the company. LPL Financial LLC increased its holdings in shares of Agilon Health by 213.4% during the 4th quarter. LPL Financial LLC now owns 44,055 shares of the company’s stock worth $30,000 after buying an additional 30,000 shares during the last quarter. CIBC Bancorp USA Inc. purchased a new position in shares of Agilon Health in the 3rd quarter worth $34,000. Merit Financial Group LLC acquired a new position in Agilon Health in the fourth quarter valued at $35,000. Focus Partners Advisor Solutions LLC acquired a new position in Agilon Health in the fourth quarter valued at $53,000. Finally, Alpine Global Management LLC purchased a new stake in Agilon Health during the fourth quarter valued at about $84,000.

Analyst Upgrades and Downgrades

AGL has been the subject of several research analyst reports. Weiss Ratings lowered Agilon Health from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 27th. Wall Street Zen raised Agilon Health from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Barclays set a $111.00 target price on Agilon Health and gave the stock an “equal weight” rating in a report on Thursday, August 6th. TD Cowen reissued a “hold” rating and set a $55.00 target price (up from $17.00) on shares of Agilon Health in a research report on Monday, May 11th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Agilon Health from a “hold” rating to a “buy” rating and raised their price target for the company from $33.00 to $49.00 in a report on Thursday, May 7th. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $97.70.

Agilon Health Stock Performance

NYSE:AGL opened at $93.74 on Tuesday. The firm has a 50-day moving average of $105.44 and a two-hundred day moving average of $61.69. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.08 and a quick ratio of 1.08. The stock has a market cap of $1.57 billion, a P/E ratio of -6.57 and a beta of 3.01. Agilon Health, Inc. has a 1-year low of $7.48 and a 1-year high of $133.04.

Agilon Health (NYSE:AGL) last announced its earnings results on Wednesday, August 5th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.90. Agilon Health had a negative return on equity of 119.38% and a negative net margin of 3.92%.The business had revenue of $1.49 billion for the quarter, compared to analyst estimates of $1.45 billion. On average, research analysts expect that Agilon Health, Inc. will post -2.95 earnings per share for the current fiscal year.

Agilon Health Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.